Skip to content

A comparative study on the application of micuronium and rocuronium in rapid sequential induction of tracheal intubation under general anesthesia

A comparative study on the application of micuronium and rocuronium in rapid sequential induction of tracheal intubation under general anesthesia

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032571
Enrollment
Unknown
Registered
2020-05-02
Start date
2020-05-18
Completion date
Unknown
Last updated
2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tracheal intubation

Interventions

Mica?:intubation after mivacurium injection
Rocu?:intubation after rocuronium injection

Sponsors

Department of Anesthesiology, Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective operation under general anesthesia with tracheal intubation; 2. Patients aged 18-65 years; 3. The American Society of anesthesiologists (ASA) was graded I-II; 4. Patients with malampati airway grade I-II; 5. Patients willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe respiratory diseases, COPD, asthma and airway hyperresponsiveness; 2. Patients with severe cardiovascular diseases, such as coronary heart disease, severe valvular disease, etc; 3. Patients with abnormal liver and kidney function; 4. Patients with severe electrolyte imbalance; 5. Neuromuscular system diseases: patients who have used neuromuscular blockers within one week, and those who have recently used drugs that interfere with neuromuscular excitation conduction, such as antiepileptics, hormones, furosemide, aminoglycoside antibiotics, etc; 6. Objects with high risk of backflow and misabsorption; 7. Those who were previously allergic to micuronium, rocuronium or other muscle relaxants; 8. Patients with known plasma cholinesterase deficiency; 9. Pregnant or lactating women; 10. Patients who have participated in any drug clinical trials within 30 days before the start of the study; 11. Other conditions that the researchers think are not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Proportion of patients in each group with excellent or clinically acceptable intubation condition;

Secondary

MeasureTime frame
Cormack-Lehane grade;Cooper's tracheal intubation scores;SBP, DBP, MAP, HR, SpO2 of each time point;time of intubation;time of RSI;attempt of intubation;Skin flushing, lung wheezing rale;

Countries

China

Contacts

Public ContactXiaoguang Zhang

Zhongshan Hospital Affiliated to Fudan University

zhangxg@fudan.edu.cn+86 13641995733

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026